Fidelity Investments
ELVN icon

Fidelity Investments’s Enliven Therapeutics ELVN Stock Holding History

Fidelity Investments’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$509M Buy
10,025,017
+3,195,771
+47% +$136M 0.02% 547
2026
Q1 		$268M Sell
6,829,246
-278,389
-4% -$7.71M 0.01% 739
2025
Q4 		$109M Sell
7,107,635
-21,561
-0.3% -$430K 0.01% 1135
2025
Q3 		$146M Sell
7,129,196
-430,705
-6% -$8.68M 0.01% 1000
2025
Q2 		$152M Buy
7,559,901
+950,372
+14% +$18M 0.01% 937
2025
Q1 		$130M Buy
6,609,529
+113,658
+2% +$2.45M 0.01% 982
2024
Q4 		$146M Buy
6,495,871
+199,692
+3% +$5.18M 0.01% 954
2024
Q3 		$161M Buy
6,296,179
+601,611
+11% +$13.9M 0.01% 906
2024
Q2 		$133M Sell
5,694,568
-551,725
-9% -$11.6M 0.01% 934
2024
Q1 		$110M Buy
6,246,293
+1,085,051
+21% +$16.6M 0.01% 1017
2023
Q4 		$71.4M Buy
5,161,242
+1,485,029
+40% +$18.2M 0.01% 1150
2023
Q3 		$50.2M Sell
3,676,213
-325,398
-8% -$5.48M ﹤0.01% 1239
2023
Q2 		$81.7M Buy
4,001,611
+838,129
+26% +$16.9M 0.01% 1081
2023
Q1 		$69.3M Buy
3,163,482
+3,139,646
+13,172% +$63.9M 0.01% 1119
2022
Q4 		$390K Buy
+23,836
New +$381K ﹤0.01% 2799
2022
Q2 		– Sell
-92,540
Closed -$696K – 5040
2022
Q1 		$696K Sell
92,540
-409,999
-82% -$2.7M ﹤0.01% 2880
2021
Q4 		$4.52M Sell
502,539
-75,134
-13% -$985K ﹤0.01% 2392
2021
Q3 		$9.43M Sell
577,673
-83,810
-13% -$1.74M ﹤0.01% 2152
2021
Q2 		$20.9M Buy
661,483
+99,847
+18% +$3.1M ﹤0.01% 1835
2021
Q1 		$19M Sell
561,636
-91,143
-14% -$4.63M ﹤0.01% 1827
2020
Q4 		$57.6M Buy
652,779
+33,653
+5% +$2.82M 0.01% 1268
2020
Q3 		$50.4M Buy
619,126
+205,280
+50% +$18.5M 0.01% 1188
2020
Q2 		$45.7M Buy
413,846
+146,221
+55% +$16.4M 0.01% 1203
2020
Q1 		$17.2M Buy
+267,625
New +$17.1M ﹤0.01% 1465

Other funds holding ELVN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Fidelity Investments's ELVN Position: Q2 2026 in Review

Fidelity Investments increased its Enliven Therapeutics (ELVN) stake by 47% in Q2 2026, buying an estimated $136M and bringing the position to 10,025,017 shares worth $509M. The position accounts for 0.02% of the portfolio, ranked #547.

Fidelity Investments first reported a position in ELVN in Q1 2020 and has held it in 24 quarters since. 211 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Fidelity Investments held 10,025,017 shares of Enliven Therapeutics worth $509M as of Q2 2026.
  • Fidelity Investments bought 3,195,771 Enliven Therapeutics shares in Q2 2026, an estimated $136M.
  • Enliven Therapeutics made up 0.02% of Fidelity Investments's portfolio in Q2 2026, its #547 holding.
  • Fidelity Investments first reported a position in Enliven Therapeutics in Q1 2020 and has held it in 24 quarters since.
  • 211 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.